Table 2.
Results for the Ames bacterial reverse mutation assay with and without metabolic activation, 2 independent assays.
| TA 1535 | TA 1537 | TA 98 | TA 100 | TA 102 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Doses (μ/plate) | Nb revertants/plate | Induction ratio (a) | Nb revertants/plate | Induction ratio (a) | Nb revertants/plate | Induction ratio (a) | Nb revertants/plate | Induction ratio (a) | Nb revertants/plate | Induction ratio (a) |
| Without metabolic activation | ||||||||||
| Assay 1 | ||||||||||
| (b) | 1338.7 | 97.7 | 655.3 | 131.1 | 523.3 | 43.6 | 1320.0 | 8.4 | 1645.3 | 8.2 |
| 0 | 18.8 | — | 4.8 | — | 14.7 | — | 150.7 | — | 168.5 | — |
| 50 | 15.3 | 0.8 | 4.7 | 1.0 | 14.7 | 1.0 | 143.0 | 0.9 | 173.7 | 1.0 |
| 150 | 12.3 | 0.7 | 5.7 | 1.2 | 10.0 | 0.7 | 148.3 | 1.0 | 197.7 | 1.2 |
| 500 | 13.0 | 0.7 | 5.7 | 1.2 | 7.0 | 0.5 | 142.7 | 0.9 | 165.3 | 1.0 |
| 1500 | 13.0 | 0.7 | 5.7 | 1.2 | 6.3 | 0.4 | 100.7 | 0.7 | 132.3 | 0.8 |
| 3000 | 10.7 | 0.6 | 89.7 | 0.5 | ||||||
| 5000 | 4.3 | 0.9 | 5.3 | 0.4 | 36.3 | 0.2 | ||||
| Assay 2 | ||||||||||
| (b) | 427.3 | 67.8 | 466.0 | 141.2 | 550.0 | 41.4 | 491.0 | 5.1 | 753.3 | 5.0 |
| 0 | 7.3 | — | 3.3 | — | 14.3 | — | 9507 | — | 134.2 | — |
| 50 | 6.3 | 0.9 | 3.0 | 0.9 | 11.0 | 0.8 | 90.3 | 0.9 | 132.7 | 1.0 |
| 150 | 5.7 | 0.8 | 5.3 | 1.6 | 10.7 | 0.7 | 85.7 | 0.9 | 132.7 | 1.0 |
| 500 | 5.0 | 0.7 | 2.0 | 0.6 | 12.7 | 0.9 | 81.0 | 0.8 | 133.7 | 1.0 |
| 1500 | 3.3 | 0.5 | 1.3 | 0.4 | 8.3 | 0.6 | 90.7 | 0.9 | 115.3 | 0.9 |
| 3000 | 4.3 | 0.6 | 91.7 | 0.7 | ||||||
| 5000 | 0.7 | 0.2 | 6.7 | 0.5 | 63.0 | 0.7 | ||||
|
| ||||||||||
| With metabolic activation | ||||||||||
| Assay 1 | ||||||||||
| (c) | 327.3 | 44.8 | 228.3 | 61.7 | 1494.7 | 78.7 | 1625.3 | 153 | 801.3 | 5.0 |
| 0 | 7.0 | — | 5.0 | — | 19.3 | — | 111.3 | — | 235.3 | — |
| 50 | 11.7 | 1.7 | 10.3 | 2.1 | 16.7 | 0.9 | 141.3 | 1.3 | 164.0 | 0.7 |
| 150 | 9.3 | 1.3 | 5.3 | 1.1 | 17.0 | 0.9 | 154.0 | 1.4 | 187.3 | 0.8 |
| 500 | 11.3 | 1.6 | 5.7 | 1.1 | 24.3 | 1.3 | 155.0 | 1.4 | 163.3 | 0.7 |
| 1500 | 6.7 | 1.0 | 8.0 | 1.6 | 22.3 | 1.2 | 139.7 | 1.3 | 139.0 | 0.6 |
| 3000 | 49.3 | 0.2 | ||||||||
| 5000 | 8.3 | 1.2 | 3.0 | 0.6 | 21.7 | 1.1 | 140.7 | 1.3 | ||
| Assay 2 | ||||||||||
| (c) | 242.7 | 20.2 | 220.0 | 34.9 | 2405.3 | 80.2 | 1680.0 | 15.9 | 791.3 | 2.7 |
| 0 | 10.2 | — | 6.8 | — | 33.3 | — | 103.0 | — | 280.3 | — |
| 50 | 11.3 | 1.1 | 7.7 | 1.1 | 23.3 | 0.7 | 99.3 | 1.0 | 183.7 | 0.7 |
| 150 | 9.0 | 0.9 | 9.0 | 1.3 | 30.0 | 0.9 | 82.7 | 0.8 | 260.7 | 0.9 |
| 500 | 8.3 | 0.8 | 7.3 | 1.1 | 23.7 | 0.7 | 91.3 | 0.9 | 176.3 | 0.6 |
| 1500 | 11.3 | 1.1 | 4.3 | 0.6 | 18.3 | 0.5 | 87.3 | 0.8 | 162.3 | 0.6 |
| 3000 | 64.3 | 0.2 | ||||||||
| 5000 | 4.7 | 0.5 | 0.7 | 0.8 | 19.0 | 0.6 | 66.0 | 0.6 | ||
The second assay in presence of metabolic activation was carried out following the preincubation method. (a) Induction Ratio = number of revertants in the treated/number of revertants in the controlReference positive compounds (μg/plate). (b) TA1535 and TA100: Sodium azide 1; TA1537: 9-amino-acridine 50; TA98: 2-nitrofluorene 2; TA102: Mitomycin C 0.125. (c ) TA1535, TA1537, TA98, TA100: 2-anthramine 2 (without pre-incubation), 1 (with pre-incubation); TA102: benzo(a)pyrene 2.